Search

everythinglearnresearchcommunity

for

Search:↓

3α-AdiolG is a good marker for androgen activity in women with excessive hair growth and decreases with anti-androgen treatment.

The chemicals 17βC and its methyl ester can block the effects of testosterone on hamster skin but not the effects of DHT.

Cyproterone acetate effectively reduced hair growth in hirsute patients by lowering androgen levels and altering androgen metabolism.

3α, 17β-androstanediol-glucuronide is not a useful marker for androgen excess but may help monitor certain treatments.

Women with female pattern hair loss have higher levels of certain androgens, suggesting increased androgen exposure to hair follicles.

ERβ has potential in treating prostate cancer and neurodegenerative diseases, but human studies are needed before clinical use.

Women with hyperandrogenism have higher androgen levels and lower SHBG, which may contribute to conditions like excessive hair growth and early puberty.

The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.

Creating stronger blockers for skin enzymes might lead to better treatment for conditions like acne and excessive hair growth.

Hormone treatments in transsexual individuals reduce hair growth and oil production in male-to-females and increase them in female-to-males.

Finasteride safely lowers DHT levels without affecting testosterone.

Androgens significantly affect female hair loss, and hormonal treatments may help.

Some women with excess hair growth have a hormone condition that can't be diagnosed by blood or urine tests alone.

Coumarin derivatives show promise as anti-estrogenic agents for treating breast cancer, with some in clinical trials.

Male hormones and their receptors play a key role in hair loss and skin health, with potential new treatments being explored.

The document concludes that early diagnosis and treatment of Congenital Adrenal Hyperplasia are crucial for preventing serious health issues and improving patient outcomes.

Cholesterol sulfate buildup due to a genetic mutation disrupts the skin barrier, leading to the scaling skin seen in X-linked ichthyosis.

FPHL is a common, age-related, genetic hair loss with unclear causes and limited treatment options.

New treatments for male hypogonadism are effective and should be personalized.

Finasteride almost fully depletes allopregnanolone in rat brains and enhances 20α-DHP, but doesn't change 3α-DHP levels.

Lower levels of certain brain chemicals are linked to worse PTSD symptoms in men.

Androgen conjugates might be better indicators of skin sensitivity to hormones in women with excessive hair growth.

The skin's ability to produce hormones is linked to various skin conditions, and better understanding this process could lead to new treatments.

The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.

The document concludes that more research is needed to understand excessive hair growth in women with normal hormone levels and regular ovulation.

Finasteride affects urinary steroid profiles and can potentially hide steroid abuse in sports drug testing.

Certain 4-azasteroids are effective at blocking the enzyme that processes testosterone in human skin and could help treat acne, excessive hair growth, and male pattern baldness.

NcoA4 may have roles beyond helping control gene activity, possibly affecting cell behavior and stability.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

Finasteride and dutasteride reduce neurosteroid production, possibly helping treat glioblastoma.